Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1950 | Inhaled sedation Wiki | 0.71 |
| drug4344 | Zofin Wiki | 0.71 |
| drug2008 | Intravenous sedation Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.12 |
| D055371 | Acute Lung Injury NIH | 0.12 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This is a multi-center, open-label study evaluating the safety of Allocetra-OTS, in 5 subjects with severe COVID-19 and respiratory dysfunction. Subjects, who will be identified as suffering from COVID-19, will be recruited. After signing an informed consent by the patient and, within 24+6 hours following the time of eligibility (time 0), on Day 1, eligible recipient subjects will receive single intravenous (IV) administration of investigational product as described below. Subjects will be hospitalized for COVID-19, and later as medically indicated. Following investigational product (IP) administration (Day 1), subjects will be followed for efficacy and safety assessments through 28 days.
Description: Incidence rates and severity of any Adverse Events (AE) and Serious Adverse Events (SAE)
Measure: Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE) Time: 28 days follow upDescription: Recovery from COVID-19 will be determined by the following measures: The percentage of subjects reporting to 'Asymptomatic' by the NIH classification and the number of days to reach this classification, and/or The percentage of subjects negative for SARS-CoV-2 RNA (by PCR) and the number of days for viral clearance (negative PCR results)
Measure: Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness Time: 28 days follow upDescription: Incidence rate of Mortality from any cause
Measure: Mortality Time: 28 days follow upDescription: Respiratory function will be assessed by measuring the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2). Patients with PaO2/FiO2 ratio < 300mmHg are considered severe patients. • The PaO2/FiO2 ratio and its change from the baseline value will be measured on days, 3, 5, 7, 14, and 28.
Measure: Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2/FiO2 ratio Time: On days, 3, 5, 7, 14, and 28 during 28 days follow upDescription: Cumulative days in the Intensive care unit (ICU) or COVID-19 ICU or COVID-19 department and/or in hospital.
Measure: Hospitalization Time: 28 days follow upDescription: Number of ventilator-free days.
Measure: Life support Time: 28 days follow upDescription: Change from baseline of the new NIH Patient Classification for the severity of illness.
Measure: Clinical status by the new NIH Patient Classification for the severity of illness Time: 28 days follow upDescription: Change from baseline of National Early Warning Score (NEWS2).
Measure: Clinical status by NEWS2 Time: 28 days follow upDescription: Percentage of subjects reporting each severity rating on a 7-point ordinal scale at day 28 as follows: Death. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, requiring supplemental oxygen. Hospitalized, not requiring supplemental oxygen. Not hospitalized, limitation on activities. Not hospitalized, no limitations on activities.
Measure: Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale Time: 28 days follow upDescription: Time to improvement of one category from admission using this 7-point ordinal scale, as follows: Death. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, requiring supplemental oxygen. Hospitalized, not requiring supplemental oxygen. Not hospitalized, limitation on activities. Not hospitalized, no limitations on activities.
Measure: Support measurements: improvement of severity rating on a 7-point ordinal scale Time: 28 days follow upDescription: Evaluation of clearance of the virus using PCR (Negative for SARS-CoV-2 RNA) on days 14 and 28 (if not negative before).
Measure: Virus Clearance Time: Within the 28 days follow up, tested on days 14 and 28Description: Serum concentrations (pg/ml) of cytokines, chemokines, complement, hematopoietic growth factors, and other immunomodulating factors (including HMGB1) will be measured before and after the infusion of Allocetra-OTS and periodically throughout 28 days follow up.
Measure: Exploratory: Serum cytokines/chemokines and immunomodulating factors Time: 28 days follow upDescription: Differential blood counts will be performed before and after the infusion of Allocetra-OTS and periodically throughout 28 days follow up.
Measure: Exploratory: complete blood counts Time: 28 days follow upDescription: Histone and cell-free DNA plasma levels will be measured before and after the infusion of Allocetra-OTS and periodically throughout 28 days follow up.
Measure: Exploratory: Histone and cell-free DNA levels Time: 28 days follow upThis is a multi-center, open-label study evaluating the safety of Allocetra-OTS, in up to 24 subjects with severe COVID-19 and respiratory dysfunction. Subjects, who will be identified as suffering from COVID-19, will be recruited. After signing an informed consent by the patient and, within 24+6 hours following the time of eligibility (time 0), on Day 1, eligible recipient subjects will receive single intravenous (IV) administration of investigational product as described below. Subjects will be hospitalized for COVID-19, and later as medically indicated. Following the investigational product (IP) administration (Day 1), subjects will be followed for efficacy and safety assessments through 28 days.
Description: Incidence rates and severity of any Adverse Events (AE) and Serious Adverse Events (SAE)
Measure: Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE) Time: 28 days follow upDescription: Recovery from COVID-19 will be determined by the following measures: The percentage of subjects reporting to 'Asymptomatic' by the NIH classification and the number of days to reach this classification, and/or The percentage of subjects negative for SARS-CoV-2 RNA (by PCR) and the number of days for viral clearance (negative PCR results)
Measure: Preliminary Efficacy: Recovery from COVID-19 as determined by negative PCR or asymptomatic by the NIH classification for the severity of illness Time: 28 days follow upDescription: Incidence rate of Mortality from any cause
Measure: Mortality Time: 28 days follow upDescription: Respiratory function will be assessed by measuring the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2). Patients with PaO2/FiO2 ratio < 300mmHg are considered severe patients. • The PaO2/FiO2 ratio and its change from the baseline value will be measured on days, 3, 5, 7, 14, and 28.
Measure: Preliminary Efficacy: To assess prevention of respiratory deterioration associated with COVID-19 by measuring the PaO2/FiO2 ratio Time: On days, 3, 5, 7, 14, and 28 during 28 days follow upDescription: Cumulative days in the Intensive care unit (ICU) or COVID-19 ICU or COVID-19 department and/or in hospital.
Measure: Hospitalization Time: 28 days follow upDescription: Number of ventilator-free days.
Measure: Life support Time: 28 days follow upDescription: Change from baseline of the new NIH Patient Classification for the severity of illness.
Measure: Clinical status by the new NIH Patient Classification for the severity of illness Time: 28 days follow upDescription: Change from baseline of National Early Warning Score (NEWS2).
Measure: Clinical status by NEWS2 Time: 28 days follow upDescription: Percentage of subjects reporting each severity rating on a 7-point ordinal scale at day 28 as follows: Death. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, requiring supplemental oxygen. Hospitalized, not requiring supplemental oxygen. Not hospitalized, limitation on activities. Not hospitalized, no limitations on activities.
Measure: Support measurements: percentage of subjects reporting each severity rating on a 7-point ordinal scale Time: 28 days follow upDescription: Time to improvement of one category from admission using this 7-point ordinal scale, as follows: Death. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Hospitalized, on non-invasive ventilation or high flow oxygen devices. Hospitalized, requiring supplemental oxygen. Hospitalized, not requiring supplemental oxygen. Not hospitalized, limitation on activities. Not hospitalized, no limitations on activities.
Measure: Support measurements: improvement of severity rating on a 7-point ordinal scale Time: 28 days follow upDescription: valuation of clearance of the virus using PCR (Negative for SARS-CoV-2 RNA) on days 14 and 28 (if not negative before).
Measure: Virus Clearance Time: Within the 28 days follow up, tested on days 14 and 28Description: Serum concentrations (pg/ml) of cytokines, chemokines, complement, hematopoietic growth factors, and other immunomodulating factors (including HMGB1) will be measured before and after the infusion of Allocetra-OTS and periodically throughout 28 days follow up.
Measure: Exploratory: Serum cytokines/chemokines and immunomodulating factors Time: 28 days follow upDescription: Differential blood counts will be performed before and after the infusion of Allocetra-OTS and periodically throughout 28 days follow up.
Measure: Exploratory: complete blood counts Time: 28 days follow upDescription: Histone and cell-free DNA plasma levels will be measured before and after the infusion of Allocetra-OTS and periodically throughout 28 days follow up.
Measure: Exploratory: Histone and cell-free DNA levels Time: 28 days follow upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports